usually the compounds of the invention were purified by column chromatography auto column on an teledyne isco combiflash with a silica column unless noted otherwise compounds 1 through 13 were prepared in a similar manner to the method described in the general scheme the starting materials and the results are tabulated below in table 1 for each case compounds were synthesized and tested for s1p1 activity using the gtp u03b3 35 s binding assay these compounds may be assessed for their ability to activate or block activation of the human s1p1 receptor in cells stably expressing the s1p1 receptor gtp u03b3 35 s binding was measured in the medium containing mm hepes 25 ph 7 4 mgcl 2 10 nacl 100 dithitothreitol 0 5 digitonin 0 003 0 2 nm gtp u03b3 35 s and 5 u03bcg membrane protein in a volume of 150 u03bcl test compounds were included in the concentration range from 0 08 to 5 000 nm unless indicated otherwise membranes were incubated with 100 u03bcm 5 u2032 adenylylimmidodiphosphate for 30 min and subsequently with 10 u03bcm gdp for 10 min on ice drug solutions and membrane were mixed and then reactions were initiated by adding gtp u03b3 35 s and continued for 30 min at 25 u00b0 c reaction mixtures were filtered over whatman gf b filters under vacuum and washed three times with 3 ml of ice cold buffer hepes 25 ph7 4 mgcl 2 10 and nacl 100 filters were dried and mixed with scintillant and counted for 35 s activity using a u03b2 counter agonist induced gtp u03b3 35 s binding was obtained by subtracting that in the absence of agonist.